<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>50</patient-age><report-id>PHHY2012ES112260</report-id><gender>male</gender><reactions><reaction>Inadequate antidiuretic hormone secretion</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>TRILEPTAL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>RAMIPRIL </drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DOBUPAL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LYRICA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>OMEPRAZOLE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Pain</indication><indication>Hypertension</indication><indication>Depression</indication></indications><patient-age>50</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Spain</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053141_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133937</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012ES112260</safetyreportid>
		<primarysourcecountry>ES</primarysourcecountry>
		<occurcountry>ES</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-05</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-05</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012ES112260</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>ES</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>ES</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>50</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="1">Male</patientsex>
			<reaction>
				<primarysourcereaction>Inadequate antidiuretic hormone secretion</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Inappropriate antidiuretic hormone secretion</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Inappropriate antidiuretic hormone secretion</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201010</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20101020</reactionenddate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>Blood corticotrophin</testname>
				<testresult>803</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Blood corticotrophin</testname>
				<testresult>803</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111011</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Blood pressure</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Blood sodium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101020</testdate>
				<testname>Blood sodium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111007</testdate>
				<testname>Blood sodium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111011</testdate>
				<testname>Blood sodium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood urea</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111007</testdate>
				<testname>Blood urea</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111011</testdate>
				<testname>Blood urea</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Urine analysis</testname>
				<testresult>271.805</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Urine analysis</testname>
				<testresult>271.805</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>TRILEPTAL</medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationnumb>21-014</drugauthorizationnumb>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>300 mg, daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain</drugindication>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2010</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2010-10-01</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OXCARBAZEPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inappropriate antidiuretic hormone secretion</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inappropriate antidiuretic hormone secretion</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>RAMIPRIL </medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2010-09-20</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2010-10-07</drugenddate>
				<drugtreatmentduration>18</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RAMIPRIL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inappropriate antidiuretic hormone secretion</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inappropriate antidiuretic hormone secretion</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>DOBUPAL</medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugstructuredosagenumb>150</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>150 mg, UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Depression</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>VENLAFAXINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>LYRICA</medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREGABALIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>OMEPRAZOLE</medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugstructuredosagenumb>20</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>20 mg, daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2009-11-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OMEPRAZOLE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012ES112260, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>via <Semaphore x="1906806" class="Disease or Finding" value="Ewing Sarcoma" score="1.00" ID="C4817">ES </Semaphore>AGEMED (336101440) Health Authority on 05 Dec 2012. This report refers to 50-year old male patient. Concomitant medication included <Semaphore x="949575" class="Medicine" value="Omeprazole" score="0.49" ID="273990">omeprazole </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown). The patient received <Semaphore x="1296815" class="Medicine" value="Trileptal" score="0.74" ID="252131">Trileptal </Semaphore>(<Semaphore x="962232" class="Medicine" value="OXcarbazepine" score="0.49" ID="253098">oxcarbazepine</Semaphore>) for <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>at a dose of 300 mg daily from 2010 (date unspecified). The patient also received <Semaphore x="1119676" class="Medicine" value="Ramipril" score="0.74" ID="258414">ramipril </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown) for <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension</Semaphore>, Dobupal (<Semaphore x="1324715" class="Medicine - Venlafaxine hydrochloride - Dose" value="150 mg" score="0.49" ID=""><Semaphore x="1324744" class="Medicine" value="Venlafaxine hydrochloride" score="0.49" ID="249638">venlafaxine hydrochloride</Semaphore>) <Semaphore x="5689607601520641" class="Medicine - Venlafaxine hydrochloride - Dose" value="150 mg" score="0.49" ID="">150 mg </Semaphore></Semaphore><Semaphore x="5689672026030081" class="Medicine - Venlafaxine hydrochloride - Frequency" value="for" score="0.49" ID="">for </Semaphore><Semaphore x="1842410" class="Procedure" value="Depression After Stopping Dexamethasone" score="1.00" ID="C113456">depression </Semaphore>and <Semaphore x="804590" class="Medicine" value="Lyrica" score="0.74" ID="275868">Lyrica </Semaphore>(<Semaphore x="1082033" class="Medicine" value="pregabalin" score="0.49" ID="239993">pregabalin</Semaphore>) for <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain</Semaphore>. On an unknown date in Oct 2010; the patient was hospitalized due to inadequate <Semaphore x="1532179" class="Procedure" value="Antidiuretic Hormone Measurement" score="1.00" ID="C74847">antidiuretic <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore></Semaphore>secretion. The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1296815" class="Medicine" value="Trileptal" score="0.74" ID="252131">Trileptal </Semaphore>and <Semaphore x="1119676" class="Medicine" value="Ramipril" score="0.74" ID="258414">ramipril </Semaphore>was stopped on 07 Oct 2010. On an unknown date, the <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">lab </Semaphore>data revealed, Na (<Semaphore x="2817289" class="MedDRA LLT" value="Blood sodium normal" score="1.00" ID="10005804"><Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium</Semaphore>) 122 (normal </Semaphore>range not provided), <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">arterial </Semaphore><Semaphore x="3272138" class="MedDRA LLT" value="Tension" score="1.00" ID="10043268">tension </Semaphore>was 130/89 (normal range not provided), <Semaphore x="2010398" class="AnatomicStructure" value="Heart" score="1.00" ID="C12727">cardiac </Semaphore>frequency was 74 (normal range not provided), <Semaphore x="2673030" class="AnatomicStructure" value="Urine" score="1.00" ID="C13283">urine </Semaphore>Na was 46 (normal range not provided), <Semaphore x="2417537" class="Procedure" value="Potassium Measurement" score="1.00" ID="C64853">K </Semaphore>(<Semaphore x="2814900" class="MedDRA LLT" value="Blood potassium normal" score="1.00" ID="10005726"><Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium</Semaphore>) was 27 (normal </Semaphore>range not provided), <Semaphore x="1316129" class="Medicine" value="Urea" score="0.87" ID="194669">urea </Semaphore>was 116.9 (normal range not provided), <Semaphore x="2673030" class="AnatomicStructure" value="Urine" score="1.00" ID="C13283">urine </Semaphore>was 271.805 Mmol/L (normal range not provided) and <Semaphore x="1455659" class="Procedure" value="Adrenocorticotropic Hormone Measurement" score="1.00" ID="C74780">ACTH </Semaphore>(<Semaphore x="1455659" class="Procedure" value="Adrenocorticotropic Hormone Measurement" score="1.00" ID="C74780">adrenocorticotropic <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone</Semaphore></Semaphore>) was 803 Mmol/L. On 07 Oct 2011, <Semaphore x="1316129" class="Medicine" value="Urea" score="0.87" ID="194669">urea </Semaphore>was 4.1, Na (<Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium</Semaphore>) was 120, <Semaphore x="2417537" class="Procedure" value="Potassium Measurement" score="1.00" ID="C64853">K </Semaphore>was 4.1 and <Semaphore x="2804345" class="MedDRA LLT" value="Blood creatinine normal" score="1.00" ID="10005484"><Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore>was 75 (normal </Semaphore>range not provided). On 11 Oct 2011, <Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore>was 74, <Semaphore x="1316129" class="Medicine" value="Urea" score="0.87" ID="194669">urea </Semaphore>was 4.8, Na was 132 and <Semaphore x="2417537" class="Procedure" value="Potassium Measurement" score="1.00" ID="C64853">K </Semaphore>was 4.39. Action taken with Dobupal and <Semaphore x="804590" class="Medicine" value="Lyrica" score="0.74" ID="275868">Lyrica </Semaphore>was unknown. The event <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was reported as recovered on 20 Oct 2010. The <Semaphore x="1906806" class="Disease or Finding" value="Ewing Sarcoma" score="1.00" ID="C4817">ES </Semaphore>AGEMED Health Authority considered the <Semaphore x="2032443" class="Disease or Finding" value="Hospitalization Event" score="1.00" ID="C80481">event as serious (<Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore></Semaphore>). The <Semaphore x="1906806" class="Disease or Finding" value="Ewing Sarcoma" score="1.00" ID="C4817">ES </Semaphore>AGEMED Health Authority assessed the event as suspected.</narrativeincludeclinical>
				<sendercomment>Medical assessment for Trileptal: It is difficult to make a causality assessment based on reported information.

Comment for Ramipril: Based on review of available information, the event syndrome of inappropriate antidiuretic hormone secretion is confounded by multiple medications.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>